# NGM Biopharmaceuticals (United States)

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/ngm-biopharmaceuticals-united-states/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 55.5 |
| Citations | 121,297 |
| City | South San Francisco |
| Country | US |
| Description | NGM Biopharmaceuticals (United States) is a research organisation in South San Francisco, US. OpenAlex records 616 works and 121,297 citations for it. 211 researchers list it as their most recent affiliation. |
| Homepage | https://www.ngmbio.com/ |
| OpenAlex ID | https://openalex.org/I4210121250 |
| Region | California |
| Researchers | 211 |
| ROR ID | https://ror.org/01x8fkj71 |
| Type | company |
| Works | 616 |

## University papers

Showing 12 of 14.

- [Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma](https://scholariq.org/papers/clinical-activity-and-molecular-correlates-of-response-to-atezolizumab-alone-or/)
- [A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors](https://scholariq.org/papers/a-small-molecule-antagonist-of-cxcr4-inhibits-intracranial-growth-of-primary/)
- [Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas](https://scholariq.org/papers/exome-sequencing-identifies-braf-mutations-in-papillary-craniopharyngiomas/)
- [Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma](https://scholariq.org/papers/recurrent-somatic-mutations-in-acvr1-in-pediatric-midline-high-grade-astrocytoma/)
- [Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1–Selected Advanced Non–Small-Cell Lung Cancer (BIRCH)](https://scholariq.org/papers/phase-ii-trial-of-atezolizumab-as-first-line-or-subsequent-therapy-for-patients/)
- [Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant](https://scholariq.org/papers/heterogeneity-and-clinical-significance-of-esr1-mutations-in-er-positive/)
- [Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial](https://scholariq.org/papers/pictilisib-for-oestrogen-receptor-positive-aromatase-inhibitor-resistant/)
- [Childhood Cancer and Traffic-Related Air Pollution Exposure in Pregnancy and Early Life](https://scholariq.org/papers/childhood-cancer-and-traffic-related-air-pollution-exposure-in-pregnancy-and/)
- [Risk of leukemia in relation to exposure to ambient air toxics in pregnancy and early childhood](https://scholariq.org/papers/risk-of-leukemia-in-relation-to-exposure-to-ambient-air-toxics-in-pregnancy-and/)
- [IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun).](https://scholariq.org/papers/immotion150-a-phase-ii-trial-in-untreated-metastatic-renal-cell-carcinoma-mrcc/)
- [Prenatal air pollution exposure and ultrasound measures of fetal growth in Los Angeles, California](https://scholariq.org/papers/prenatal-air-pollution-exposure-and-ultrasound-measures-of-fetal-growth-in-los/)
- [LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration](https://scholariq.org/papers/loggic-firefly-2-a-phase-3-randomized-trial-of-tovorafenib-vs-chemotherapy-in/)

## University researchers

- [Jiaheng Qiu](https://scholariq.org/researchers/jiaheng-qiu/)

## University top topics

Showing 8 of 25.

- [Drug Transport and Resistance Mechanisms](https://scholariq.org/topics/drug-transport-and-resistance-mechanisms/)
- [Pharmacogenetics and Drug Metabolism](https://scholariq.org/topics/pharmacogenetics-and-drug-metabolism/)
- [Pharmacological Effects and Toxicity Studies](https://scholariq.org/topics/pharmacological-effects-and-toxicity-studies/)
- [Glioma Diagnosis and Treatment](https://scholariq.org/topics/glioma-diagnosis-and-treatment/)
- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)
- [Liver Disease Diagnosis and Treatment](https://scholariq.org/topics/liver-disease-diagnosis-and-treatment/)
- [Fibroblast Growth Factor Research](https://scholariq.org/topics/fibroblast-growth-factor-research/)
- [HIV/AIDS drug development and treatment](https://scholariq.org/topics/hiv-aids-drug-development-and-treatment/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.